POSIFLEX-TECHNOLOGY
15.3.2024 03:28:35 CET | Business Wire | Press release
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, is pleased to announce that its Haydn ZT Series - the industry's first clamshell POS terminal with a patented modular design and exceptional serviceability - and its Gen9 Base, which integrates a thermal printer and power supply for maximum space efficiency, have been awarded the iF DESIGN AWARD 2024 in the discipline of Product in the Public/Retail category by the Hannover-based iF International Forum Design GmbH, which is one of the most coveted accolades in the world of design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314845350/en/
Posiflex Wins the iF DESIGN AWARD 2024 for Haydn ZT Series and Gen9 Base (Graphic: Business Wire)
The Posiflex Haydn ZT Series and Gen9 Base stood out from a field of nearly 11,000 entries from 72 countries, impressing the 132-strong jury of independent experts from around the world with innovative designs and technical excellence aimed at delivering the highest levels of convenience and value to users and consumers.
Haydn ZT Series: The Industry's First Clamshell POS Terminal
The Posiflex Haydn ZT Series redefines the mechanical structure of POS terminals with the world's first clamshell design. This design simplifies maintenance tasks by allowing the monitor to be effortlessly lifted with just a slide of the hidden lever. It provides convenient access to internal modular components and facilitates easy and seamless repairs, replacements, and upgrades. Such innovation promises to significantly reduce downtime in case of a crash, minimizing inconvenience and financial losses associated with such incidents.
Gen9 Base: A Multi-Functional POS Terminal Base
The Gen9 Base is a multi-functional POS terminal base that integrates a built-in high-speed 250mm/second thermal receipt printer with auto-cutter concealed within its lightweight, screwless housing, in addition to hidden I/O, power and cabling designs, all of which combine to achieve a clean and stylish look and a clutter-free countertop. The POS terminal base also offers the option of a second monitor, expandable up to 15.6 inches, for maximum space efficiency and convenience for users and consumers.
Owen Chen, CEO of Posiflex Technology remarked, "Winning the iF DESIGN AWARD 2024 for our Haydn ZT Series and Gen9 Base is a testament to Posiflex's relentless pursuit of excellence in product design and innovation. Posiflex has been committed to pushing the boundaries of technological innovation to enhance the experiences of our customers worldwide.”
Being recognized by the esteemed iF International Forum Design GmbH reaffirms our position as a leader in the industry and motivates us to continue delivering cutting-edge solutions that meet the evolving needs of our customers. The Haydn ZT POS terminal series and Gen9 Base epitomize our dedication to innovation-driven entrepreneurship and unwavering focus on putting our customers first.
More information about The Haydn ZT Series and Gen9 Base can be found at: https://ifdesign.com/en/search?find=posiflex
About POSIFLEX Group
Posiflex Group is a leading global Commercial Internet of Things (CIoT) platform powered by smart Online-to-Offline (O2O) and Software-agnostic Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314845350/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom